Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study.

Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, Lucraft H, Gilbertson R, Tait DM, Walker DA, Pizer BL, Imeson J, Lashford LS; International Society of Paediatric Oncology; United Kingdom Children's Cancer Study Group.

J Clin Oncol. 2003 Apr 15;21(8):1581-91.

PMID:
12697884
2.

Impact of radiotherapy parameters on outcome in the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study of preradiotherapy chemotherapy for M0-M1 medulloblastoma.

Taylor RE, Bailey CC, Robinson KJ, Weston CL, Ellison D, Ironside J, Lucraft H, Gilbertson R, Tait DM, Saran F, Walker DA, Pizer BL, Lashford LS; United Kingdom Children's Cancer Study Group Brain Tumour Committee; International Society of Paediatric Oncology.

Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1184-93.

PMID:
15001263
3.

Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91.

Kortmann RD, Kühl J, Timmermann B, Mittler U, Urban C, Budach V, Richter E, Willich N, Flentje M, Berthold F, Slavc I, Wolff J, Meisner C, Wiestler O, Sörensen N, Warmuth-Metz M, Bamberg M.

Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):269-79.

PMID:
10661332
4.

Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy.

Taylor RE, Bailey CC, Robinson KJ, Weston CL, Walker DA, Ellison D, Ironside J, Pizer BL, Lashford LS.

Eur J Cancer. 2005 Mar;41(5):727-34. Epub 2005 Jan 18.

PMID:
15763649
5.

Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.

Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, Bayer L, LaFond D, Donahue BR, Marymont MH, Muraszko K, Langston J, Sposto R.

J Clin Oncol. 2006 Sep 1;24(25):4202-8.

PMID:
16943538
6.

A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).

Allen J, Donahue B, Mehta M, Miller DC, Rorke LB, Jakacki R, Robertson P, Sposto R, Holmes E, Vezina G, Muraszko K, Puccetti D, Prados M, Chan KW.

Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1006-11. doi: 10.1016/j.ijrobp.2008.09.019. Epub 2009 Apr 7.

7.

Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy.

Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, Mulne L, Boyett J, D'Angio G, Wechsler-Jentzsch K, et al.

J Neurosurg. 1994 Nov;81(5):690-8.

PMID:
7931615
8.

High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031).

Tarbell NJ, Friedman H, Polkinghorn WR, Yock T, Zhou T, Chen Z, Burger P, Barnes P, Kun L.

J Clin Oncol. 2013 Aug 10;31(23):2936-41. doi: 10.1200/JCO.2012.43.9984. Epub 2013 Jul 15.

9.

No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.

Massimino M, Gandola L, Spreafico F, Biassoni V, Luksch R, Collini P, Solero CN, Simonetti F, Pignoli E, Cefalo G, Poggi G, Modena P, Mariani L, Potepan P, Podda M, Casanova M, Pecori E, Acerno S, Ferrari A, Terenziani M, Meazza C, Polastri D, Ravagnani F, Fossati-Bellani F.

Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1358-63. doi: 10.1016/j.ijrobp.2008.06.1930. Epub 2008 Nov 18.

PMID:
19019566
10.

Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma.

Merchant TE, Kun LE, Krasin MJ, Wallace D, Chintagumpala MM, Woo SY, Ashley DM, Sexton M, Kellie SJ, Ahern V, Gajjar A.

Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):782-7. Epub 2007 Sep 24.

11.

Progressive disease in children with medulloblastoma/PNET during preradiation chemotherapy.

Tornesello A, Mastrangelo S, Piciacchia D, Bembo V, Colosimo C, Di Rocco C, Mastrangelo R.

J Neurooncol. 1999;45(2):135-40.

PMID:
10778729
12.

Hyperfractionated Accelerated Radiotherapy (HART) with maintenance chemotherapy for metastatic (M1-3) Medulloblastoma--a safety/feasibility study.

Taylor RE, Howman AJ, Wheatley K, Brogden EE, Large B, Gibson MJ, Robson K, Mitra D, Saran F, Michalski A, Pizer BL.

Radiother Oncol. 2014 Apr;111(1):41-6. doi: 10.1016/j.radonc.2014.01.022. Epub 2014 Mar 11.

PMID:
24630538
14.

Adult medulloblastoma: multiagent chemotherapy.

Greenberg HS, Chamberlain MC, Glantz MJ, Wang S.

Neuro Oncol. 2001 Jan;3(1):29-34. doi: 10.1093/neuonc/3.1.29. Review.

15.

Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma.

Gandola L, Massimino M, Cefalo G, Solero C, Spreafico F, Pecori E, Riva D, Collini P, Pignoli E, Giangaspero F, Luksch R, Berretta S, Poggi G, Biassoni V, Ferrari A, Pollo B, Favre C, Sardi I, Terenziani M, Fossati-Bellani F.

J Clin Oncol. 2009 Feb 1;27(4):566-71. doi: 10.1200/JCO.2008.18.4176. Epub 2008 Dec 15.

PMID:
19075266
16.
17.

Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial.

Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, Massimino M, Reddingius R, Benesch M, Carrie C, Taylor R, Gandola L, Björk-Eriksson T, Giralt J, Oldenburger F, Pietsch T, Figarella-Branger D, Robson K, Forni M, Clifford SC, Warmuth-Metz M, von Hoff K, Faldum A, Mosseri V, Kortmann R.

J Clin Oncol. 2012 Sep 10;30(26):3187-93. doi: 10.1200/JCO.2011.39.8719. Epub 2012 Jul 30.

PMID:
22851561
18.

Protracted radiotherapy treatment duration in medulloblastoma.

Paulino AC, Wen BC, Mayr NA, Tannous R, Loew TW, Goldman FD, Meeks SL, Ryken TC, Buatti JM.

Am J Clin Oncol. 2003 Feb;26(1):55-9.

PMID:
12576926
19.
20.

Postoperative radiotherapy of medulloblastoma. Impact of radiation quality on treatment outcome.

Grabenbauer GG, Beck JD, Erhardt J, Seegenschmiedt MH, Seyer H, Thierauf P, Sauer R.

Am J Clin Oncol. 1996 Feb;19(1):73-7.

PMID:
8554041

Supplemental Content

Support Center